What a Positive Antibody Test Does and Does Not Tell You About Immunity

A positive antibody test tells you that your immune system has met a pathogen or a vaccine antigen and produced antibodies against it. It does not tell you that you are protected. The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention both advise against using serology to judge immunity, because the authorized tests were never validated to measure protection, and a positive result functions as an exposure marker rather than a pass. Antibodies are one layer of a multi-part defense, and a single reactive line on a lab report says little about whether that defense will hold when it is tested.

What a positive result actually measures

A serology test looks for antibodies circulating in your blood, proteins your immune system makes in response to infection or vaccination. On its own terms the test is doing something narrow and real: the FDA notes that a positive antibody result can help identify people who may have had a prior SARS-CoV-2 infection. That is a statement about your past, not your future. It confirms that your body saw an antigen and mounted a response at some point before the blood draw.

Most widely used assays report whether antibodies are present, and sometimes a numeric level, but they were designed to detect binding antibodies rather than to certify that those antibodies can stop a live virus. The FDA is explicit on the boundary: SARS-CoV-2 antibody tests do not tell you whether you have immunity that will keep you from getting COVID-19, and they should not be used to diagnose a current infection either. A positive result is evidence of contact, not a certificate of protection.

Antibodies are one arm of the response

The immune system is layered. Innate defenses respond first and without memory. Antibodies, produced by B cells, are the humoral arm. T cells coordinate the response and kill infected cells as the cellular arm. Memory B cells and memory T cells hold the template for a faster reaction months or years later. A serology test samples one of these compartments at one moment.

That matters in both directions. Circulating antibody levels often fall in the months after infection or vaccination while memory cells persist, so a lower or even negative titer does not mean protection has vanished. In the other direction, detectable antibodies do not guarantee they are the functional, neutralizing kind, present at a level that blocks infection. Binding and neutralizing antibodies are not the same thing, and standard serology usually measures the former.

Exposure marker versus validated correlate of protection

Immunology has a specific term for a lab value that reliably predicts protection: a correlate of protection. It is a measurable immune marker shown, through careful population studies, to track with a defined level of clinical protection above a validated threshold. Establishing one is demanding work, and it is specific to a given assay and a given disease.

Most antibody tests offered to the public are not validated correlates of protection. They report a signal without an agreed cutoff that means "immune." Results from different manufacturers use different units and calibrators, so a number from one assay cannot be lined up against a number from another. The FDA states plainly that the currently authorized antibody tests are not validated to evaluate immunity or protection. Reading a protective status into a titer treats an exposure marker as though it were a correlate that, for that test, has never been established.

Why the FDA and CDC advise against inferring immunity

In a safety communication first issued in May 2021, the FDA advised that results from authorized SARS-CoV-2 antibody tests should not be used to evaluate a person's level of immunity or protection at any time, and especially after vaccination. The agency's reasoning is twofold: the tests were not validated for that purpose, and if a result is misread, someone may take fewer precautions than their actual risk warrants. The CDC's interim guidelines reach the same conclusion, stating that antibody testing is not recommended to assess immunity after COVID-19 vaccination or to decide whether an unvaccinated person needs the vaccine, because none of the authorized tests were validated to measure protection.

A concrete assay detail sharpens the point. COVID-19 mRNA vaccines prompt antibodies against the spike protein, while some serology assays are built to detect antibodies against the nucleocapsid protein, a marker of natural infection. A person who responded well to vaccination can test negative on a nucleocapsid assay and misread that as failure. The result is not wrong; it is answering a different question than the one being asked.

How to read your own result

If you have a positive antibody test, the sound interpretation is modest and useful: your immune system encountered the antigen and responded. It is not a signal to drop recommended precautions, and it is not a stand-in for the vaccination schedule your clinician follows, which rests on outcome data rather than individual titers. This is general education, not medical advice, and questions about your own results or vaccination timing belong with a qualified clinician who knows your history.

The deeper lesson travels beyond one virus. An antibody is a footprint showing that something walked through. Whether the door is now locked depends on the whole system, and on evidence that a given test has actually been tied to protection. Until a test carries that validation, a positive result is best read as a record of exposure, not a guarantee of immunity.